FindTrial
Sign In

ROLE OF BLOOD CELL MARKERS IN CASE OF SEPSIS MANAGEMENT

ROLE OF NEUTROPHIL (nCD 64) AND MONOCYTIC HLA-DR (mHLA-DR) AS NEWER BIOMARKERS OF SEPSIS MANAGEMENT IN ADULT PATIENTS ADMITTED IN ICU. - BIOSEPSIS

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2019/07/020477
Enrollment
110
Registered
2019-07-31
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B998- Other infectious disease

Interventions

None listed

Sponsors

DR Ram Manohar Lohia Institute Of Medical Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients developing sepsis during observation period of 20 days with sofa score more or equal to two.

Exclusion criteria

Exclusion criteria: 1) Patientâ??s or Relativeâ??s refusal to give consent. 2) Patient who developed sepsis after 20 days. 3) Patients who developed sepsis again after recovering 4) Patient on G- CSF therapy.

Design outcomes

Primary

MeasureTime frame
To measure the expression of nCD64, mHLA-DR, PCT and CRP-Q sequentially in patients admitted to ICU.Timepoint: sepsis biomarkers on day 1,3 and day 7.—

Secondary

MeasureTime frame
To correlate the expression of nCD64, mHLA-DR, PCT and CRP-Q individually as well as in combination to predict development of sepsis and its outcomeTimepoint: after day 1,3 and day 7 sepsis biomarker results—

Countries

India

Contacts

Public ContactDR DEEPAK MALVIYA

DR RAM MANOHAR LOHIA INSTITUTE OF MEDICAL SCIENCES

drdm58@gmail.com05226692063

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026